Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma.
Schlenzka
Jana
J
University Hospital for Internal Medicine, Department of Hematology/Oncology, Heidelberg University Medical School, Heidelberg, Germany.
Moehler
Thomas M
TM
Kipriyanov
Sergey M
SM
Kornacker
Martin
M
Benner
Axel
A
Bähre
Alexandra
A
Stassar
Marike J J G
MJ
Schäfer
Holger J
HJ
Little
Melvyn
M
Goldschmidt
Hartmut
H
Cochlovius
Björn
B
D000818:Animals; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000276:immunology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D006131:Growth Inhibitors / Q000494:pharmacology; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D017452:Receptors, IgG / Q000276:immunology*; D011994:Recombinant Proteins / Q000494:pharmacology; D013792:Thalidomide / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays / Q000379:methods
D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D006131:Growth Inhibitors; D017452:Receptors, IgG; D011994:Recombinant Proteins; D013792:Thalidomide